Table 1.
Characteristics of CD5+ DLBCL patients in the two cohorts.
| Variables | Derivation cohort | Validation cohort | P | χ 2/Z |
|---|---|---|---|---|
| n = 131 | n = 64 | |||
| Age a | 65 (53–70) | 57 (56–70) | 0.327 | −0.98 |
| Alb a | 36.1 (30.2–40.7) | 35 (34.7–39.3) | 0.604 | −0.519 |
| NE a | 3.7 (2.3–4.5) | 2.9 (2.8–3.7) | 0.743 | −0.329 |
| RBC a | 4.2 (4.0–4.5) | 3.9 (3.3–4.1) | 0.100 | −1.644 |
| LYC a | 1.4 (1.0–1.5) | 1.7 (1.2–2.7) | 0.924 | −0.095 |
| LDH a | 217 (162–310) | 288 (218–689) | 0.492 | −0.687 |
| Fer a | 188.5 (124.1–294.0) | 137.9 (129.5–274.0) | 0.394 | −0.853 |
| β2-MG a | 2.2 (2.0–3.9) | 3.7 (2.3–7.3) | <0.001 | −4.301 |
| Gender: male b | 70 (53.4%) | 30 (46.9%) | 0.389 | 0.741 |
| ECOG PS (2–4) b | 27 (20.6%) | 21 (32.8%) | 0.063 | 3.450 |
| Stage III/IV b | 70 (53.4%) | 46 (71.9%) | 0.014 | 6.066 |
| BM involvement b | 9 (6.9%) | 10 (15.6%) | 0.001 | 20.185 |
| CNS involvement b | 16 (12.2%) | 16 (25.0%) | 0.024 | 5.124 |
| B symptoms b | 37 (28.2%) | 14 (22.9%) | 0.541 | 0.373 |
| Bulky b | 3 (2.3%) | 4 (6.6%) | 0.139 | 2.194 |
| Non-GCB b | 74 (56.5%) | 45 (70.3%) | 0.063 | 3.455 |
| Ki-67 ≥0.9 b | 24 (18.3%) | 10 (15.6%) | 0.641 | 0.217 |
| MYC b | 81 (61.8%) | 27 (42.2%) | 0.001 | 13.389 |
| BCL-2+ b | 88 (67.2%) | 41 (64.1%) | 0.666 | 0.186 |
| BCL-6+ b | 85 (64.9%) | 30 (46.9%) | 0.016 | 5.764 |
a
Continuous variables were presented in median and interquartile range.
b
Categorical variables were presented in numbers and percentages.
Alb, albumin; NE, neutrophil count; RBC, red blood cell count; LYC, lymphocyte count; LDH, lactate dehydrogenase; Fer, ferritin; β2-MG, β2-microglobulin; BM involvement, bone marrow involvement; CNS involvement, central nervous system involvement.